Claim Your New User Special: Get your second month free ▶ Second Month Free

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Medtronic
Dow
McKinsey
Mallinckrodt

Last Updated: May 26, 2022

FERAHEME Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

When do Feraheme patents expire, and what generic alternatives are available?

Feraheme is a drug marketed by Covis and is included in one NDA. There is one patent protecting this drug and one Paragraph IV challenge.

This drug has thirteen patent family members in ten countries.

The generic ingredient in FERAHEME is ferumoxytol. There is one drug master file entry for this compound. Two suppliers are listed for this compound. Additional details are available on the ferumoxytol profile page.

DrugPatentWatch® Litigation and Generic Entry Outlook for Feraheme

A generic version of FERAHEME was approved as ferumoxytol by SANDOZ INC on January 15th, 2021.

  Sign up for a Free Trial

Drug patent expirations by year for FERAHEME
Drug Prices for FERAHEME

See drug prices for FERAHEME

Recent Clinical Trials for FERAHEME

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Bryan AllenPhase 1
Holden Comprehensive Cancer CenterPhase 1
University of Wisconsin, MadisonEarly Phase 1

See all FERAHEME clinical trials

Paragraph IV (Patent) Challenges for FERAHEME
Tradename Dosage Ingredient Strength NDA ANDAs Submitted Submissiondate
FERAHEME Injection ferumoxytol 30 mg/mL, 17 mL single-use vials 022180 1 2015-12-04

US Patents and Regulatory Information for FERAHEME

FERAHEME is protected by one US patents.

Patents protecting FERAHEME

Heat stable colloidal iron oxides coated with reduced carbohydrates and carbohdrate derivatives
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 AB RX Yes Yes See Plans and Pricing See Plans and Pricing Y Y See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Expired US Patents for FERAHEME

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 See Plans and Pricing See Plans and Pricing
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 See Plans and Pricing See Plans and Pricing
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 See Plans and Pricing See Plans and Pricing
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 See Plans and Pricing See Plans and Pricing
Covis FERAHEME ferumoxytol SOLUTION;INTRAVENOUS 022180-001 Jun 30, 2009 See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >Patent No. >Patent Expiration

International Patents for FERAHEME

See the table below for patents covering FERAHEME around the world.

Country Patent Number Title Estimated Expiration
Denmark 1169062 See Plans and Pricing
Japan 2011046752 HEAT STABLE COLLOIDAL IRON OXIDE COATED WITH REDUCED CARBOHYDRATE AND CARBOHYDRATE DERIVATIVE See Plans and Pricing
European Patent Office 1169062 OXYDES DE FER COLLOIDAUX THERMOSTABLES RECOUVERTS DE CARBOHYDRATES REDUITS ET DES DERIVES DE CARBOHYDRATES (HEAT STABLE COATED COLLOIDAL IRON OXIDES) See Plans and Pricing
Japan 5064612 See Plans and Pricing
Japan 2002541218 See Plans and Pricing
Austria 446108 See Plans and Pricing
>Country >Patent Number >Title >Estimated Expiration

Supplementary Protection Certificates for FERAHEME

Patent Number Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
1169062 C01169062/01 Switzerland See Plans and Pricing PRODUCT NAME: FERUMOXYTOL; REGISTRATION NO/DATE: SWISSMEDIC 62033 17.08.2012
1169062 1290043-7 Sweden See Plans and Pricing PRODUCT NAME: FERUMOXYTOL; REG. NO/DATE: EU/1/12/774/001 20120615
1169062 C300558 Netherlands See Plans and Pricing PRODUCT NAME: FERUMOXYTOL IN IEDERE DOOR HET BASISOCTROOI BESCHERMDE VORM; REGISTRATION NO/DATE: EU/1/12/774/001-002 20120615
1169062 300558 Netherlands See Plans and Pricing PRODUCT NAME: FERUMOXYTOL IN IEDERE DOOR HET BASISOCTROOI BESCHERMDE VORM; REGISTRATION NO/DATE: EU/1/12/774/001-002 20120615
1169062 92114 Luxembourg See Plans and Pricing PRODUCT NAME: FERUMOXYTOL
1169062 2012C/052 Belgium See Plans and Pricing PRODUCT NAME: FERUMOXYTOL; AUTHORISATION NUMBER AND DATE: EU/1/12/774/001 20120620
>Patent Number >Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Mallinckrodt
Harvard Business School
Johnson and Johnson
McKinsey
AstraZeneca
Medtronic

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.